We are live on ! Find out more
JSPR icon

Jasper Therapeutics

10 hedge funds and large institutions have $102M invested in Jasper Therapeutics in 2021 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 53 closing their positions.

New
Increased
Maintained
Reduced
Closed

26% more capital inflows, than outflows

Capital inflows: $104M | Capital outflows: $82.8M

50% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 2

56.95% less ownership

Funds ownership: 84.19% → 27.25% (-57%)

82% less funds holding

Funds holding: 56 → 10 (-46)

87% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 53

Holders
10
Holders Change
-46
Holders Change %
-82.14%
% of All Funds
0.17%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
7
Increased
1
Reduced
2
Closed
53
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

JSPR Hedge Fund Activity: Q3 2021 in Review

10 of the 5,733 institutional investors tracked by Wall St. Rank reported a position in Jasper Therapeutics (JSPR) for Q3 2021, worth a combined $102M — up 22% from $83.7M a quarter earlier.

Sellers outnumbered buyers: 53 funds closed out of JSPR and 7 opened new positions — a net loss of 46 holders — while 2 trimmed existing stakes and 1 added.

The largest buyer was Abingworth, opening a new position worth an estimated $57.5M. The largest seller was Mizuho Securities USA, exiting entirely with an estimated $6.49M sold.

  • 10 institutional investors held Jasper Therapeutics (JSPR) as of Q3 2021, down from 56 in Q2 2021.
  • Funds reported $102M of Jasper Therapeutics stock for Q3 2021, up 22% quarter-over-quarter.
  • 7 funds opened new Jasper Therapeutics positions in Q3 2021 and 53 closed out, a net change of -46 holders.
  • The largest Jasper Therapeutics buyer in Q3 2021 was Abingworth, an estimated $57.5M added.
  • The largest Jasper Therapeutics seller in Q3 2021 was Mizuho Securities USA, an estimated $6.49M sold.

Based on aggregated 13F filings for Q3 2021.